Pulmonary Drugs Market, by Drug Class, Application, Distribution Channel, and Region - Global Trends, and Forecast, 2022 - 2028

Pulmonary Drugs Market, by Drug Class, Application, Distribution Channel, and Region - Global Trends, and Forecast, 2022 - 2028

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
Market Dynamics
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2021, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.  
Key features of the study:

This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pulmonary drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Detailed Segmentation:

Global Pulmonary Drugs Market, By Drug Class:

Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others

Global Pulmonary Drugs Market, By Application:

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others

Global Pulmonary Drugs Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

Global Pulmonary Drugs Market, By Geography:

North America

By Drug Class:

Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others

By Application:

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

U.S.
Canada

Latin America

By Drug Class:

Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others

By Application:

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Drug Class:

Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others

By Application:

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Drug Class:

Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others

By Application:

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Drug Class:

Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others

By Application:

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

GCC
Israel
Rest of Middle East

Africa

By Drug Class:

Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others

By Application:

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

South Africa
Central Africa
North Africa

Company Profiles

Sanofi SA*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited

“*” marked represents similar segmentation in other categories in the respective section.